Valneva Reports Sustained 94% Seroresponse Five Years After a Single Dose of Chikungunya Vaccine IXCHIQ®Noticia de empresa10 nov 2026ENValneva SECompany newsroom
Valneva Announces Positive Phase 2 Results for Tetravalent Shigella Vaccine Candidate S4V2Noticia de empresa9 nov 2026ENValneva SECompany newsroom
Valneva to Report Nine-Month 2026 Consolidated Financial Results on November 24, 2026Noticia de empresa4 nov 2026ENValneva SECompany newsroom
Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare ConferencesNoticia de empresa14 oct 2026ENValneva SECompany newsroom
Valneva Provides Update on IXCHIQ® in the United KingdomNoticia de empresa7 oct 2026ENValneva SECompany newsroom
Pfizer and Valneva’s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines AgencyNoticia de empresa14 ago 2026ENValneva SECompany newsroom
Valneva Reports Half Year 2026 Financial Results and Provides Corporate UpdatesNoticia de empresa13 ago 2026ENValneva SECompany newsroom
Valneva to Report First Half 2026 Consolidated Financial Results on August 13, 2026Noticia de empresa22 jul 2026ENValneva SECompany newsroom
Valneva Announces Successful Outcome of its Annual General MeetingNoticia de empresa25 jun 2026ENValneva SECompany newsroom
Valneva Announces Availability of Documentation for its Annual General MeetingNoticia de empresa4 jun 2026ENValneva SECompany newsroom
Valneva to Participate at U.S. and European Investor Conferences in JuneNoticia de empresa28 may 2026ENValneva SECompany newsroom
Valneva Reports First Quarter 2026 Financial Results and Provides Corporate UpdatesNoticia de empresa13 may 2026ENValneva SECompany newsroom
Valneva to Report First Quarter 2026 Consolidated Financial Results on May 13, 2026Noticia de empresa5 may 2026ENValneva SECompany newsroom
Valneva Announces the Successful Completion of an €84 million Reserved OfferingNoticia de empresa30 abr 2026ENValneva SECompany newsroom
Valneva to Participate in Multiple Events at the 26th World Vaccine Congress in Washington DCNoticia de empresa26 mar 2026ENValneva SECompany newsroom